UNSPSC 51263004: Urapidil

This classification denotes an adrenergic alpha-1 receptor antagonist and antihypertensive agent with the molecular formula C20H29N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A78GF17HJS, chemically known as 2,4(1h,3h)-pyrimidinedione, 6-((3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyl- (9ci) but generally known as urapidil, which bears US NIH Compound Identifier 5639. European Medicines Agency schedules Urapidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11384MIG.

UNSPSC 51263004 Urapidil, a Commodity code, covers pharmaceutical products procured by state and local health agencies, though recent opportunities show a mismatch between the code's nominal scope and actual solicitation activity. The two recent state and local postings tagged to this code involve naloxone procurement and a therapeutic pharmacy initiative inquiry rather than urapidil-specific purchases. State and local health departments and human services commissions are the primary issuing bodies under this code, sourcing emergency medications and pharmacy benefit management capabilities to support public health and employee benefit programs.

The geographic activity visible in recent postings spans Florida and Texas. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Texas Health and Human Services Commission released an RFI (HHS0017013) posted April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative, exploring contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows limited recent activity directly aligned with urapidil procurement; the available opportunities reflect broader pharmaceutical and pharmacy benefit sourcing rather than a single active drug class.